Post
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Head And Neck Squamous …
Rigosertib sodium by Traws Pharma for Squamous Cell Carcinoma: Likelihood of Approval
Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Squamous Cell Carcinoma. According to …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Non-Small Cell Lung Cancer: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Small Cell Lung Cancer. …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Sarcomas: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Sarcomas. According to GlobalData, …
SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Breast Cancer: Likelihood of Approval
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Breast Cancer. According to …
JS-006 by Shanghai Junshi Biosciences for Non-Small Cell Lung Cancer: Likelihood of Approval
JS-006 is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Non-Small Cell Lung Cancer. According …
JS-006 by Shanghai Junshi Biosciences for Solid Tumor: Likelihood of Approval
JS-006 is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Solid Tumor. According to GlobalData, …
JS-006 by Shanghai Junshi Biosciences for Hepatocellular Carcinoma: Likelihood of Approval
JS-006 is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, …
Rhenium (186Re) obisbemeda by Plus Therapeutics for Head And Neck Cancer: Likelihood of Approval
Rhenium (186Re) obisbemeda is under clinical development by Plus Therapeutics and currently in Phase II for Head And Neck Cancer. …
Alvotech moves to bring its Humira biosimilar to US market
Hot on the heels of a US Food and Drug Administration (FDA) approval for Alvotech and Teva Pharmaceuticals’ Simlandi (adalimumab-ryvk), …
XH-001 by NeoCura Bio-Medical Technology for Solid Tumor: Likelihood of Approval
XH-001 is under clinical development by NeoCura Bio-Medical Technology and currently in Phase II for Solid Tumor. According to GlobalData, …
FHND-71 by Protheragen for Solid Tumor: Likelihood of Approval
FHND-71 is under clinical development by Protheragen and currently in Phase I for Solid Tumor. According to GlobalData, Phase I …
DM-5167 by Dime Bio for Solid Tumor: Likelihood of Approval
DM-5167 is under clinical development by Dime Bio and currently in Phase I for Solid Tumor. According to GlobalData, Phase …
Rigosertib sodium by Traws Pharma for Metastatic Melanoma: Likelihood of Approval
Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Metastatic Melanoma. According to GlobalData, …
Vertex’s pain drug suzetrigine advances in FDA approval process
Vertex Pharmaceuticals’ suzetrigine, previously named VX-548, is steadily advancing along its rolling submission approval pathway okayed by the US Food …